Sandra Milligan - 29 May 2025 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role: Director
Signature: /s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol: SYRE
Transactions as of: 29 May 2025
Net transactions value: $0
Form type: 4
Filing time: 02 Jun 2025, 16:37:14 UTC
Previous filing: 29 Jan 2025
Next filing: 26 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Milligan Sandra	Director	221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM	/s/ Heidy King-Jones, as Attorney-in-Fact	02 Jun 2025	0001859810

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRE	Stock Option (Right to Buy)	Award	$0	+25,000		$0.000000	25,000	29 May 2025	Common Stock	25,000	$15.55	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.